Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

1013002

USP

Allopurinol

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

1H-Pyrazolo(3,4-d)pyrimidin-4-ol, 4-Hydroxypyrazolo(3,4-d)pyrimidine, 4-Hydroxypyrazolo[3,4-d]pyrimidine, HPP

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C5H4N4O
Numéro CAS:
315-30-0
Poids moléculaire :
136.11
Numéro MDL:
MFCD00599413
Code UNSPSC :
41116107
ID de substance PubChem :
329748958
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

allopurinol

Fabricant/nom de marque

USP

Pf

>300 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

15-25°C

Chaîne SMILES 

O=C1NC=Nc2[nH]ncc12

InChI

1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)

Clé InChI

OFCNXPDARWKPPY-UHFFFAOYSA-N

Informations sur le gène

human ... XDH(7498)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Allopurinol USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Allopurinol Compounded Oral Suspension
  • Allopurinol Tablets

Actions biochimiques/physiologiques

Inhibitor of xanthine oxidase and de novo pyrimidine biosynthesis. A classical agent in treatment of hyperuricemia and gout.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1013035

Allopurinol Related Compound C, United States Pharmacopeia (USP) Reference Standard

A0350040

Allopurinol impurity D, European Pharmacopoeia (EP) Reference Standard

A0350010

Allopurinol impurity A, European Pharmacopoeia (EP) Reference Standard

A0350000

Allopurinol, European Pharmacopoeia (EP) Reference Standard

A0350020

Allopurinol impurity B, European Pharmacopoeia (EP) Reference Standard

A0350030

Allopurinol impurity C, European Pharmacopoeia (EP) Reference Standard

A0350050

Allopurinol impurity E, European Pharmacopoeia (EP) Reference Standard

1013046

Allopurinol Related Compound D, United States Pharmacopeia (USP) Reference Standard

1013013

Allopurinol Related Compound B, United States Pharmacopeia (USP) Reference Standard

1013024

Allopurinol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1013068

Allopurinol Related Compound E, United States Pharmacopeia (USP) Reference Standard

1013079

Allopurinol Related Compound F, United States Pharmacopeia (USP) Reference Standard

BP870

Allopurinol, British Pharmacopoeia (BP) Reference Standard

PHR2005

Allopurinol Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2006

Allopurinol Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2007

Allopurinol Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2008

Allopurinol Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2009

Allopurinol Related Compound E, Pharmaceutical Secondary Standard; Certified Reference Material

BP832

Allopurinol impurity B, British Pharmacopoeia (BP) Reference Standard

BP844

Allopurinol impurity D, British Pharmacopoeia (BP) Reference Standard

BP845

Allopurinol impurity E, British Pharmacopoeia (BP) Reference Standard

BP843

Allopurinol impurity C, British Pharmacopoeia (BP) Reference Standard

Pictogrammes

Skull and crossbones
GHS06

Mention d'avertissement

Danger

Mentions de danger

H301,H317

Classification des risques

Acute Tox. 3 Oral - Skin Sens. 1

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Dino Premilovac et al.
Diabetologia, 57(12), 2586-2595 (2014-09-13)
High sodium (HS) effects on hypertension are well established. Recent evidence implicates a relationship between HS intake and insulin resistance, even in the absence of hypertension. The aim of the current study was to determine whether loss of the vascular
Jennifer J DuPont et al.
American journal of physiology. Renal physiology, 306(12), F1499-F1506 (2014-04-25)
Oxidative stress promotes vascular dysfunction in chronic kidney disease (CKD). We utilized the cutaneous circulation to test the hypothesis that reactive oxygen species derived from NADPH oxidase and xanthine oxidase impair nitric oxide (NO)-dependent cutaneous vasodilation in CKD. Twenty subjects
Timothy Pearson et al.
PloS one, 9(5), e96378-e96378 (2014-05-31)
Skeletal muscle generation of reactive oxygen species (ROS) is increased following contractile activity and these species interact with multiple signaling pathways to mediate adaptations to contractions. The sources and time course of the increase in ROS during contractions remain undefined.
C C Wen et al.
Clinical pharmacology and therapeutics, 97(5), 518-525 (2015-02-14)
The first-line treatment of hyperuricemia, which causes gout, is allopurinol. The allopurinol response is highly variable, with many users failing to achieve target serum uric acid (SUA) levels. No genome-wide association study (GWAS) has examined the genetic factors affecting allopurinol
Lisa K Stamp et al.
Rheumatology (Oxford, England), 53(11), 1958-1965 (2014-06-06)
The aims of this study were to establish whether, in patients with gout, MPO is released from neutrophils and urate is oxidized to allantoin and if these effects are attenuated by allopurinol. MPO, urate, allantoin and oxypurinol were measured in
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique